Glioblastoma Clinical Trial
Official title:
A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa®) and an Oral Formulation of Irinotecan (Camptosar™) in Children With Refractory Solid Tumors
The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects. Studies performed in the laboratory have shown that ZD1839 helps make available the orally administered irinotecan. In this study the intravenous (given into the vein) formula of irinotecan will be given orally on days 1-5 and days 8-12. The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12. Each course of treatment will consist of 21 days. The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will be an intravenous administration. All other doses and subsequent courses will consist of an orally administered dose.
This is a phase I study to estimate the maximum tolerated dose and the dose limiting
toxicities of the intravenous formulation of irinotecan given orally in combination with a
fixed dose of oral gefitinib. This trial will use the EWOC method, which is an adaptive dose
escalation scheme. The method is fully adaptive and makes use of all the information
available at the time of each dose assignment, and directly addresses the ethical need to
control the probability of overdosing. It is designed to approach the maximum tolerated dose
(MTD) as fast as possible.
In this study the intravenous formulation of irinotecan will be given orally on days 1-5 and
days 8-12 (dose level begins at 5 mg/m2 ). One patient will be treated at each dose level of
irinotecan until moderate toxicity is observed. At the level where moderate toxicity is
observed, the cohort size will be increased to 2 patients. Dosages will then be increased
until the development of DLT as guided by the EWOC model. The estimated MTD will be
continually reassessed using all data from preceding patients. The toxicity data of all
patients enrolled in the trial are used to update the dose-toxicity relationship and to
guide the next escalation/de-escalation. The calculation will be carried out with EWOC
software. Patients will be enrolled and the dose assigned is determined based on previous
participants' toxicity. The dose of ZD1839 will be a fixed dose and will be administered
orally on days 1-12 - [150 mg/m2 (maximum 250 mg)] Each course of treatment will consist of
21 days. The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will
be an intravenous administration. All other doses and subsequent courses will consist of an
orally administered dose.
Secondary Objectives Include:
- To describe dose-limiting toxicities (DLTs) of the combination of oral irinotecan and
ZD1839 and to define their duration and reversibility.
- To investigate the pharmacokinetics of oral irinotecan and ZD1839 when given in
combination in children with recurrent malignant solid tumors.
- To describe the relationship between pharmacokinetic parameters and toxicity.
- To describe any antitumor effects within the confines of a phase I study.
- To examine tumor expression of ErbB1 and/or ABCG2 with respect to pharmacokinetics and
response.
- To examine the pharmacogenetic determinants of ZD1839 and irinotecan pharmacokinetics
and pharmacodynamics.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05664243 -
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Recruiting |
NCT05635734 -
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03679754 -
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
|
Phase 1 | |
| Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
| Terminated |
NCT03927222 -
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
|
Phase 2 | |
| Recruiting |
NCT03897491 -
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03587038 -
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT04391062 -
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03661723 -
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT02655601 -
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
|
Phase 2 | |
| Completed |
NCT02206230 -
Trial of Hypofractionated Radiation Therapy for Glioblastoma
|
Phase 2 | |
| Completed |
NCT03493932 -
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
|
Phase 1 | |
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Completed |
NCT03018288 -
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
|
Phase 2 | |
| Not yet recruiting |
NCT04552977 -
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
| Terminated |
NCT02905643 -
Discerning Pseudoprogression vs True Tumor Growth in GBMs
|